Cargando…
From Resistance to Sensitivity: Insights and Implications of Biphasic Modulation of Autophagy by Sunitinib
Sunitinib, a multityrosine kinase inhibitor, is currently the standard first-line therapy in metastatic renal cell carcinoma (mRCC) and is also used in treating patients with pancreatic neuroendocrine and imatinib-resistant gastrointestinal stromal tumors (GIST). Nevertheless, most patients eventual...
Autores principales: | Abdel-Aziz, Amal Kamal, Abdel-Naim, Ashraf B., Shouman, Samia, Minucci, Saverio, Elgendy, Mohamed |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641351/ https://www.ncbi.nlm.nih.gov/pubmed/29066973 http://dx.doi.org/10.3389/fphar.2017.00718 |
Ejemplares similares
-
Corrigendum: From Resistance to Sensitivity: Insights and Implications of Biphasic Modulation of Autophagy by Sunitinib
por: Abdel-Aziz, Amal Kamal, et al.
Publicado: (2018) -
Molecular Determinants of Sensitivity or Resistance of Cancer Cells Toward Sanguinarine
por: Saeed, Mohamed E. M., et al.
Publicado: (2018) -
Biphasic Effect of Pirfenidone on Angiogenesis
por: Gan, Donghao, et al.
Publicado: (2022) -
The yin yang of sunitinib: One drug, two doses, and multiple outcomes
por: Elgendy, Mohamed
Publicado: (2017) -
Impact of Global DNA Methylation in Treatment Outcome of Colorectal Cancer Patients
por: Fouad, Mariam A., et al.
Publicado: (2018)